Simulations Plus, Inc. is the leading developer of Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) and Physiologically-Based Pharmacokinetic (PBPK) modeling and simulation software for the pharmaceutical and biotechnology, industrial chemical, cosmetic, herbicide, and food ingredient industries today. Our software allows pharmaceutical scientists to predict certain key potential endpoints and dynamics, in silico, thereby reducing research & development costs and helping clients make better projects decisions... sooner.
Founded in 1996, Simulations Plus employs over 30 employees (22 with Ph.D. or M.S. degrees) and is publicly-traded on the NASDAQ stock exchange (ticker symbol = SLP). Our headquarters are based in Lancaster, California, with trusted distributors handling sales and scientific support in Asian territories. All of the top 20 pharmaceutical companies, plus numerous mid- and small-sized companies and all major regulatory agencies, license our software.
Consulting services: our team of highly-skilled scientists is available to assist with your discovery and development activities on a project-by-project basis. With the acquisition of Cognigen Corporation in 2014, we are now able to offer expanded pharmacodynamic modeling services, NONMEM analysis, and regulatory report writing assistance. The ultimate goal of the merger is to develop tools and systems which bridge PBPK modeling with clinical trial data analysis.
Our expertise, combined with our best-in-class software, provides you with modeling and simulation analyses, from discovery through late-stage clinical development, which can greatly improve your decision-making process.
Founded in 1996, Simulations Plus employs over 30 employees (22 with Ph.D. or M.S. degrees) and is publicly-traded on the NASDAQ stock exchange (ticker symbol = SLP). Our headquarters are based in Lancaster, California, with trusted distributors handling sales and scientific support in Asian territories. All of the top 20 pharmaceutical companies, plus numerous mid- and small-sized companies and all major regulatory agencies, license our software.
Consulting services: our team of highly-skilled scientists is available to assist with your discovery and development activities on a project-by-project basis. With the acquisition of Cognigen Corporation in 2014, we are now able to offer expanded pharmacodynamic modeling services, NONMEM analysis, and regulatory report writing assistance. The ultimate goal of the merger is to develop tools and systems which bridge PBPK modeling with clinical trial data analysis.
Our expertise, combined with our best-in-class software, provides you with modeling and simulation analyses, from discovery through late-stage clinical development, which can greatly improve your decision-making process.
Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »
